Risperdal Lawsuit News: New Defense Motion Filed in Pennsylvania Risperdal Litigation, Bernstein Liebhard LLP Reports
New York, New York (PRWEB) October 10, 2014 -- Risperdal lawsuits (http://www.risperdallawsuitcenter.com/) that allege the atypical antipsychotic medication caused men and boys to develop gynecomastia (male breast growth) continue to move forward in a mass tort litigation now underway in Pennsylvania’s Philadelphia Court of Common Pleas, Bernstein Liebhard LLP reports. According to a Motion filed on October 7, 2014, Defendants Excerpta Medica, Inc. and Elsevier, Inc. are requesting that the Court adopt an Amended Short Form Complaint that would require a Plaintiff to affirmatively indicate whether or not they intend to pursue claims against Excerpta and/or Elsevier. The Motion notes that the use of the Amended Short Form Complaint will clarify a lawsuit’s actual defendants from the outset, and avoid the administrative burdens of having dismissals filed as to defendants Plaintiffs never intended to sue. (In Re: Risperdal Litigation, Case Number 100300296).
“Our Firm is representing numerous plaintiffs in Risperdal gynecomastia claims that have been filed in this litigation. We are pleased to see the proceeding moving forward, and will continue to monitor developments closely,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal consultations to men and boys who allegedly developed gynecomastia due to their use of Risperdal.
Risperdal Litigation
According to court documents, more than 700 Risperdal lawsuits are currently pending in the Pennsylvania litigation. All of these complaints allege that the medication caused serious side effects, including gynecomastia in boys and men. The lawsuits also accuse Johnson & Johnson and Janssen Pharmaceuticals of concealing these risks, and of improperly marketing the drug for unapproved uses. The proceeding’s first trial of a claim involving gynecomastia allegations is scheduled to begin on November 3, 2014.
In November 2013, Johnson & Johnson and Janssen Pharmaceuticals agreed to pay $2.2 million to settle charges brought by the U.S. Department of Justice involving the marketing of Risperdal and other medications. While the companies did not admit any wrongdoing in resolving civil charges regarding the promotion of Risperdal for off-label use in children, they did plead guilty to a criminal misdemeanor and acknowledged that they had improperly marketed the drug for use in elderly dementia patients. (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)
Men and boys who allegedly developed gynecomastia due to their use of Risperdal may be able to pursue their own claim against the manufacturers of the drug. To learn more about filing a Risperdal lawsuit, please visit Bernstein Liebhard LLP’s website. For a free case review, please call 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Felecia L. Stern, Esq.
info (at) consumerinjurylawyers (dot) com
http://www.risperdallawsuitcenter.com/
https://plus.google.com/115936073311125306742?rel=author
Felecia L. Stern, Risperdal Lawsuit Information Center, http://www.risperdallawsuitcenter.com/, +1 800-511-5092, [email protected]
Share this article